Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Microbix Biosystems Inc. (T:MBX)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily
Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for MBX within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 05, 2019 07:00 ET
Microbix Quality Products Attain European Registration
Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, is pleased to announce European registration for four innovative in-vitro diagnostic (IVD) control products for evaluating performance,...
Read full article
Aug 12, 2019 07:00 ET
Microbix Reports Results for Q3 Fiscal 2019
Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its third quarter and nine months of fiscal 2019, the three-month and nine-month periods ending June 30, 2019 (“Q3” & “YTD”),...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.03
--
--
Price to Sales - TTM
1.61
16.11
12.72
Price to Book - most recent quarter
2.02
3.11
2.78
Price to Cash Flow per share - TTM
55.78
--
12.38
Price to Free Cash Flow per share - TTM
--
4.12
18.61
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Aug 31, 201938,38423,806
Aug 15, 201914,57810,300
Jul 31, 20194,2780
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Microbix Biosystems Inc is a Canada-based life science company and manufacturer of viral and bacterial antigens and cell, culture-based biological products and technologies. The Company has developed and acquired two technologies: Kinlytic Urokinase and LumiSort. Kinlytic Urokinase is a biologic thrombolytic drug used to treat blood clots. LumiSort is a technology for ultra-rapid and efficient sorting of somatic cells that can be used to enrich cell populations of interest. The Company's catalogue of antigens covers over 30 bacterial and viral pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually-transmitted and insect-borne diseases.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $MBX.CA

  • No tweets found

StockTwits